Posts tagged “Merck”

February 9, 2016

Premium Lock Twitter vs terror; diabetes cure?; McKinney's loss; LinkedIn plunge; Merck earnings

Bulldog In today's Bulldog wrapup of technology and life science news: Twitter cracks down on terror; J&J pursues diabetes cure; McKinney loses major account; LinkedIn's shares plunge 44 percent; and Merck sales miss estimates.

January 21, 2016

Premium Lock GSK, Pfizer, Merck join drug industry-government alliance to fight superbugs

Infections Drug giants GlaxoSmithKline, Pfizer and Merck, all of which have a big presence in North Carolina, are teaming with dozens of other companies and governments to form an alliance to fight "superbugs."

January 15, 2016

Premium Lock Merck settles on investor Vioxx claims

Merck  Drugmaker, Merck, (NYSE:MRK), said it will pay $830 million and attorney's fees, to sell investor claims related to its drug Vioxx.

Tags: Merck
January 6, 2016

Premium Lock Merck CEO is eager for deals, sees strong prospects for new drugs

Merck's chief executive says the drugmaker is "raring to go" on deals this year, particularly for small and midsize acquisitions of companies or their experimental drugs. Merck is one of the largest life science employers in the Triangle.

Merck CEO Kenneth Frazier Merck CEO Kenneth Frazier

June 24, 2015

Premium Lock Merck job cuts hit contractors at Durham vaccine plant

Merck  Drug giant Merck, one of the largest life science industry employers in the Triangle, cut jobs at its big vaccine manufacturing plant in Durham this week. The cuts are the latest to hit RTP area drug companies.

April 30, 2015

Premium Lock Quintiles, Biogen, Martin Marietta, GSK, Pfizer, Merck crack InformationWeek elite list

InformationWeek's annual "Elite 100" corporate list for innovative technology includes several located in or have big operations around the Triangle as well as the City of Asheville.

The Elite 100 The Elite 100

June 9, 2014

Premium Lock Merck to buy Idenix in $3.85 billion deal

Merck  Merck said Monday it would buy Idenix Pharmaceuticals for $3.85 billion and plans to combine the company's two most promising drugs to produce a faster, more effective cure for hepatitis C.

February 4, 2014

Premium Lock GSK, others team with NIH in $230M effort to fight Alzheimer's, other diseases

Alzheimer's  Data generated from the work will be made public for other scientists to use, a move that the U.S. National Institutes of Health called groundbreaking. The targeted diseases are some of the most prevalent conditions among Americans, costing the nation billions of dollars in treatment and lost productivity.

January 9, 2014

Premium Lock Report: Novartis looks to deal vaccine, animal health businesses to Merck

Novartis reportedly is in negotiations with fellow drug giant Merck about a $10 billion asset swap that would include the Novartis human vaccines and animal health businesses. Novartis operates a huge vaccine in Holly Springs and is building an R&D center in RTP.

Novartis plant in Holly Springs Novartis plant in Holly Springs

October 28, 2013

Premium Lock Merck narrows full-year revenue forecast as key drug sales slip

Merck  Merck the second-biggest U.S. drugmaker which operates a huge facility in Durham, narrowed its full-year forecast after sales of its top-seller, diabetes pill Januvia, declined.

October 1, 2013

Premium Lock Merck to cut 8,500 more jobs, shifts its R&D efforts

Merck  The second largest U.S. drug maker, which has a large vaccine plant operation in Durham, is cutting thousands of jobs and consolidating its headquarters in New Jersey.

May 9, 2013

Premium Lock GSK, Merck slash cost of cervical cancer vaccine 95% for use in poorest countries

Vaccine Two drug giants with substantial operations in North Carolina are drastically cutting the costs of their cervical cancer vaccines as part of the first large-scale effort to get the shots to girls in the world's poorest areas.

February 15, 2013

Premium Lock Merck to pay $688M to settle suit from investors over cholesterol drugs

Merck  The deal settles two long-running lawsuits brought by investors who alleged the drugmaker delayed releasing bad news on its blockbuster cholesterol drugs to prevent a drop in sales.

Updated December 10, 2012

Premium Lock Chemistry among people, companies is crucial to biochemistry deals

Finding the right chemistry is crucial to biotech deals, as two major life science partnerships in the Triangle have shown this year: GSK and Liquidia; Merck and Chimerix.

Drug deal Drug deal

July 25, 2012

Premium Lock Merck licenses HIV compound from RTP-based Chimerix

Fighting HIV In exchange for exclusive worldwide license and funding the drug development and commercialization costs, Merck will pay Chimerix $17.5 million on top of royalties on future sales and milestone payments of up to $151 million.

May 2, 2012

Premium Lock Merck investing $15M to expand, renovate Wilson NC facility

Merck  Drug giant Merck will invest $15 million to update and expand its facility in Wilson. However, no new jobs are planned, the Wilson Times reports.

October 10, 2011

Premium Lock Merck CEO to take over as chairman Dec. 1

Merck  The drug giant also receives approval from the FDA for a drug that treats type 2 diabetes and cholesterol problems.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith